MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
25.23
+0.27
+1.06%
After Hours: 25.23 0 0.00% 17:53 12/12 EST
OPEN
24.93
PREV CLOSE
24.97
HIGH
25.28
LOW
24.45
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
35.72
52 WEEK LOW
16.10
MARKET CAP
3.19B
P/E (TTM)
84.95
1D
5D
1M
3M
1Y
5Y
1D
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark
Seeking Alpha · 1d ago
Sobi Announces CHMP's Positive Opinion For Aspaveli
NASDAQ · 1d ago
Sobi Wins Positive CHMP Opinion for Aspaveli in Rare Kidney Diseases
Reuters · 1d ago
Is Apellis Pharmaceuticals (APLS) Undervalued After Its Recent Share Price Rebound?
Simply Wall St · 3d ago
Weekly Report: what happened at APLS last week (1201-1205)?
Weekly Report · 5d ago
Why Apellis Pharmaceuticals (APLS) Is Up 10.9% After Positive EMPAVELI VALIANT Kidney Data And FDA Nod
Simply Wall St · 6d ago
Roth Capital healthcare analyst holds an analyst/industry conference call
TipRanks · 12/05 19:40
Is Apellis Pharmaceuticals a Bargain After Sharp 2025 Rebound Despite Weak PE Signals?
Simply Wall St · 12/05 17:23
More
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.